PeptiDream Inc
TSE:4587
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 168.5
2 968
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
PeptiDream Inc
PeptiDream Inc
Cost of Revenue
PeptiDream Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PeptiDream Inc
TSE:4587
|
Cost of Revenue
-¥12.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-42%
|
|
|
GNI Group Ltd
TSE:2160
|
Cost of Revenue
-¥4.4B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-39%
|
|
|
Takara Bio Inc
TSE:4974
|
Cost of Revenue
-¥18.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Cost of Revenue
-¥13.4B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-34%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Cost of Revenue
-¥13.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PeptiDream Inc
Glance View
PeptiDream Inc. engages in the biopharmaceutical business that includes research and development of non standard peptide therapeutics. The company is headquartered in Kawasaki-Shi, Kanagawa-Ken and currently employs 141 full-time employees. The company went IPO on 2013-06-11. The firm operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The firm is involved in the business centered on drug development based on special peptides. The firm's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
See Also
What is PeptiDream Inc's Cost of Revenue?
Cost of Revenue
-12.2B
JPY
Based on the financial report for Sep 30, 2024, PeptiDream Inc's Cost of Revenue amounts to -12.2B JPY.
What is PeptiDream Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-42%
Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for PeptiDream Inc have been -69% over the past three years , -49% over the past five years , and -42% over the past ten years .
You don't have any saved screeners yet
